What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?
Related Experiment Video
Updated: Feb 14, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Jean Covino1, Jennifer Hoffman
1At Pace University-Lenox Hill Hospital in New York City, Jean Covino is a professor and Jennifer Hoffman is an associate professor in the PA program. Dr. Covino also practices at Medemerge Family Practice Center in Green Brook, N.J. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Abstract:
New classes of drugs to treat type 2 diabetes are continually being developed and marketed. The FDA has issued guidance to the pharmaceutical industry that newer hypoglycemic agents should not be associated with unacceptable increases in cardiovascular risk. To date, five trials have assessed specific cardiovascular endpoints for these newer agents. Empagliflozin and liraglutide have been found to improve cardiovascular outcomes.
More Related Videos
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Drug Classes and Categories
Antihypertensive Drugs: Thiazide-Class Diuretics
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

